Rising prevalence of chronic diseases due to togavirus is the major factor driving the rubella diagnostic testing market. Increasing incidences of rubella is a direct consequence of high transmission ability of togavirus via air. Rubella infection generally affects children and adults. The infection has serious implications in pregnant women, which can lead to fetal death or congenital defects. Increasing demand for MMR vaccines for the protection of children against rubella and introduction of advance point of care diagnostic technologies such as BioPlex 2200 MMRV (varicella zoster, rubella, mumps and measles virus) by Bio Rad Laboratories are additionally propelling the growth of global rubella diagnostic testing market. In a probe to combat rubella disease, various government initiatives pertaining to research and development of advanced diagnostic techniques in emerging countries such as China and India are carried out, which is in turn expected to propel growth of market in near future. However, there is no typical drug therapy available for treatment of rubella in present, which is expected to restrain the growth of rubella diagnostic testing market over the forecast period.
The overall rubella diagnostic testing market is categorized on the basis of diagnostic testing techniques into flow cytometry, latex slide agglutination test, monoclonal antibodies, immunoassays, serological testing and clinical evaluation. These tests are typically prescribed for pregnant women along with women planning to conceive and health professionals who are in contact with pregnant women. These tests may also be performed for babies born with congenital defects.
Geographically, the entire rubella diagnostic testing market is classified into North America, Europe, Asia Pacific, Latin America and MEA. As of 2014, Europe was one of the largest market in terms of revenue share owing to the increased cases of rubella infection in this region. According to the Pan American Health Organization (PAHO) and WHO, Colombia and Latin America are declared free of rubella infection, as of 2011. However, epidemics of rubella are still present in developing regions such as Africa and South East Asia. Vaccination for rubella are not available in these regions. Thailand, Timor Leste, Macedonia, Tajikistan and Syria are accounted for largest number of rubella infection cases as of 2013. Asia Pacific region is expected to register lucrative growth over the forecast period owing to larger untapped opportunities, increasing government initiatives for development of novel vaccines and therapies and compartively lower cost of production.
The global rubella diagnostic testing market is highly fragmented due to the engagement of various established as well as emerging players in the market. Some key players operating in the market include Ortho Clinical Diagnostics, Merck & Co., Siemens AG, GlaxoSmithKline plc., Hoffmann La Roche Ltd., Bio Rad Laboratories, Inc., BioMerieux SA, Beckman Coulter Inc. and Abbott Laboratories. These companies are constantly involved in R&D for gaining competitive advantage in the global market.
Request for TOC of this report:
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com
No comments:
Post a Comment